Molecular PharmaGroup LLC
FDA inspection history in New Providence, New Jersey, 2025 to 2026
- 1
- Untitled letter
- 1
- Form 483
Every document, by year
- Untitled letter
- Form 483
2025: one Form 483; 2026: one untitled letter.
The story so far
Built from the dates and citations on the documents themselves.
- 2025–26One Form 483 and one untitled letter, at New Providence, New Jersey.
Cited most
Across all Molecular PharmaGroup observations on file
- 21 CFR 211.113(b)Control of microbiological contamination1
- 21 CFR 211.180(e)(1)General requirements1
- 21 CFR 211.42(c)(10)(vi)Design and construction features1
The complete Molecular PharmaGroup file.
All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
New Providence, New Jersey
One untitled letter and one Form 483 · 2025 to 2026 · 3 observations
Latest: Untitled letter, Feb 5, 2026 →
Documents
2 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2026-02-05 | Untitled letter Untitled letter | New Providence, New Jersey | — | $99 |
| 2025-08-11 | 483 Form 483 | New Providence, New Jersey | 3 | $99 |
Investigators on these documents
Amatul H. Marium (1)Annet R. Rajan (1)Stephenie M. Ortiz (1)
FEI number 3014413265 · most recent document Feb 5, 2026
About Molecular PharmaGroup LLC
How many FDA Form 483s has Molecular PharmaGroup LLC received?
FDA Intel has 1 Form 483 on file for Molecular PharmaGroup LLC; the most recent is dated Aug 11, 2025.
When was Molecular PharmaGroup LLC last inspected by FDA?
The most recent FDA inspection document on file for Molecular PharmaGroup LLC is a Form 483 dated Aug 11, 2025, for the site in New Providence, New Jersey.
What did FDA cite at Molecular PharmaGroup LLC?
The regulations cited most in the observations on file for Molecular PharmaGroup LLC are 21 CFR 211.113(b) (Control of microbiological contamination), 1 time; 21 CFR 211.180(e)(1) (General requirements), 1 time; 21 CFR 211.42(c)(10)(vi) (Design and construction features), 1 time.
Has Molecular PharmaGroup LLC received an FDA untitled letter?
Yes. FDA Intel has 1 FDA untitled letter on file for Molecular PharmaGroup LLC; the most recent is dated Feb 5, 2026. An untitled letter is FDA's enforcement letter for violations that don't rise to warning-letter level.